Teiichi Hirano

Molecular cloning and sequence analysis of cDNA and genomic DNA for the human cone transducin α subunit

A novel GTP binding protein (G protein) α subunit cDNA was isolated from a T cell leukemia cell line, Jurkat, utilizing polymerase chain reaction (PCR). The predicted amino acid sequence of this G protein α subunit showed the highest identity (96.6%) to bovine cone cell‐specific transducin (Tcα). The organization of the coding region of this G protein α subunit gene was composed of 8 exons and 7 introns. Northern hybridization revealed the presence of this G protein message in a retinoblastoma cell line, Y79. In Jurkat, however, the message was detectable only by reverse transcription/PCR. Taken together, this novel G protein α subunit must be human Tc.

Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study)

Complete response (CR) after treatment for multiple myeloma is associated with superior progression‐free survival (PFS). Multiple myeloma patients were prospectively recruited for induction treatment with bortezomib and dexamethasone (BD) followed by autologous hematopoietic cell transplantation (auto‐HCT) between 2010 and 2012. If patients did not achieve CR after auto‐HCT, BD consolidation therapy was added to target CR.

Serum ALP elevation early after treatment is a predictor for response in myeloma patients treated with bortezomib

Several studies have shown the predictive value of elevated serum alkaline phosphatase (ALP) level in multiple myeloma (MM) patients treated with bortezomib (BTZ). We assessed the relationship between changes in ALP levels during treatment and response. Thirty patients treated with BTZ in our hospital were analyzed retrospectively. Of the patients analyzed, 12 were male, median age was 62 years (42-86), and 11 had a history of prior chemotherapy. Eighteen patients were treated with BTZ alone or in combination with dexamethasone, while the others were treated with a combination regimen employing an alkylating agent. Seven patients had undergone autologous stem cell transplantation following BTZ therapy. Ten of 28 patients showed ALP elevation of 25% or more from the baseline at 3 weeks, and 14 of the 28 had this finding at 6 weeks. Four of 5 patients who had achieved VGPR or more showed ALP elevation of 25% or more at 3 weeks, and all five had this finding by 6 weeks. No patient without ALP elevation achieved VGPR or a better response. ALP elevation exceeding 25% from the baseline by day 42 is significantly associated with a treatment response better than VGPR (p=0.019). In conclusion, ALP elevation during BTZ treatment is a valuable prognostic marker.